President Donald Trump signed an executive order Saturday directing the FDA to expedite its review of certain psychedelic drugs already designated as breakthrough therapies, pairing a $50 million federal research commitment with a new pathway for desperately ill patients to access ibogaine under the right to try law.

The signing took place in the Oval Office on April 18, with an unusual cast of figures flanking the president: HHS Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and Bryan Hubbard, CEO of the nonprofit Americans for Ibogaine. The order targets drugs already in advanced clinical trials and aims to strip away what Trump called "unnecessary bureaucratic hurdles" that have stalled promising treatments for years.

For veterans suffering from PTSD, traumatic brain injuries, and treatment-resistant depression, the executive order represents the most aggressive federal action yet on psychedelic-assisted therapy. It comes as more than 6,000 veterans have died by suicide each year since 2001, a toll Kennedy said far exceeds combat deaths over the same period.

What the executive order does

The order directs the FDA to speed its review process for psychedelics that have already earned breakthrough therapy designation. It also mandates improved data sharing between the FDA and the Department of Veterans Affairs, and it requires HHS to accelerate research approval and access to new mental health treatments, including psychedelic therapies such as ibogaine.

Perhaps most significantly, Fox News Digital reported that the order opens a pathway for ibogaine, a psychoactive compound derived from a Central African rainforest shrub, to be administered to seriously ill patients under the existing right to try law. That provision bypasses the standard FDA approval timeline for patients who have exhausted other options.

Trump also announced a $50 million federal research investment, which he said was approved the night before the signing. That federal commitment matches a $50 million allocation Texas Republican leaders had already directed toward ibogaine research.

The FDA plans to issue national priority vouchers for three psychedelic drugs, a step that AP News reported could compress review timelines from months to weeks. The agency is also moving toward the first-ever human trials of ibogaine in the United States.

The case for ibogaine

Trump leaned heavily on a 2024 Stanford University study in making his case. That study followed 30 special operations veterans with traumatic brain injuries who underwent ibogaine treatment. The results, as Trump described them from the Oval Office, were striking.

"They experienced an 80 to 90% reduction in symptoms of depression and anxiety within one month."

A paper published in the journal Chronic Stress described ibogaine as a "psychoactive indole alkaloid" extracted from the Tabernanthe iboga shrub, used for centuries in Central African initiatory rituals. The paper found that ibogaine treatment "is reported to alleviate a spectrum of mood and anxiety symptoms" and allows patients to reprocess traumatic memories, a mechanism with direct relevance to PTSD.

The substance remains classified as a Schedule I drug, and no psychedelic has yet won FDA approval in the United States. That classification carries real political weight. As one policy expert, Ismail Lourido Ali, told Newsmax, "The stigma around Schedule I drugs is significant," but the executive order gives Republican governors and legislatures cover to fund research programs of their own.

Trump's order also includes a provision for fast rescheduling of any psychedelic drugs that ultimately win FDA approval, a step that could remove one of the largest remaining barriers to widespread clinical use.

Kennedy frames the crisis

HHS Secretary Kennedy delivered some of the starkest numbers at the signing. He said more than 14 million Americans live with serious mental illness, and one in four adults experiences a diagnosable disorder each year. Suicide rates have climbed more than 30 percent over the past two decades.

Kennedy reserved his sharpest language for the veteran population, as the administration continues to reshape its national security and veterans' affairs leadership:

"At the same time, millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatments. We owe it to our warfighters and veterans to turn over every stone to alleviate the emotional and mental health blowback from their deployments."

That framing, the gap between what existing treatments deliver and what veterans actually need, is the core of the administration's argument. Standard-of-care therapies for PTSD and traumatic brain injury leave many patients stuck. The executive order bets that psychedelic-assisted therapy can reach patients whom conventional medicine has failed.

Rogan's role and the political coalition

Joe Rogan's presence in the Oval Office was no accident. The podcaster, whose show reaches tens of millions of listeners, credited Bryan Hubbard and former Texas Governor Rick Perry with bringing the issue to his attention.

"They told me how impactful this medicine is. And having that conversation with them, millions of people got a chance to hear their story, hear the stories of all the different people that have had life-changing experiences from it."

The political coalition behind the order is broader than many observers expected. Veterans groups, conservative state leaders, and figures like Marcus Luttrell, the former Navy SEAL, have pushed for expanded psychedelic research. Veterans Affairs Secretary Doug Collins praised the order directly, as the Washington Examiner reported, saying it "opens up new possibilities for America's Veterans" as part of an "all-of-the-above strategy" on mental health.

That bipartisan energy is worth watching. The issue cuts across traditional left-right lines in ways that few policy debates do right now. But the administration moved first, and moved fast, claiming ownership of a space that could reshape mental health treatment for a generation.

The executive action fits a pattern of aggressive governance from the White House this spring, from personnel confrontations at the Federal Reserve to sweeping policy directives on immigration and law enforcement.

What remains unanswered

The order raises questions it does not yet answer. Which psychedelics beyond ibogaine fall under its scope? What funding mechanism will deliver the $50 million federal investment? And how will the FDA balance speed with the safety concerns that have kept ibogaine, a drug with known cardiac risks, on Schedule I for decades?

Trump acknowledged the tension between urgency and caution. "These treatments are currently in the advanced stages of clinical trials to ensure that they're both safe and effective for the American patients," he said. He also noted that research has been underway "for quite some time" but that previous administrations let it languish.

That is the real indictment embedded in this order. The data on veteran suicides, 6,000 a year for more than two decades, did not arrive last week. The Stanford study came out in 2024. Texas committed its $50 million before the federal government moved a dollar. For years, the bureaucratic machinery that is supposed to protect patients also kept promising treatments locked behind regulatory gates while veterans kept dying.

Democrats, meanwhile, face an uncomfortable position. They have spent years talking about mental health funding and veteran care, yet it is this administration that signed the order. As recent polling suggests, the opposition party's ability to claim credit on issues where Republicans act first continues to erode.

Whether psychedelic-assisted therapy ultimately delivers on its promise will depend on clinical results, not executive orders. But for veterans who have tried everything else and found nothing that works, a president willing to push the FDA past its institutional inertia is a start.

Sometimes the biggest obstacle to saving lives is not the science. It is the paperwork.